

PRIOR AUTHORIZATION REQUEST FORM
PHENYLKENTONUIRA

Kuvan®, Palynziq®

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: Sapropterin dihydrochloride

Non-preferred: Palynziq® (pegvaliase-pqz)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the patient have a confirmed diagnosis of phenylketonuria?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Is the patient followed by a physician who specializes in metabolic diseases?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Is the patient followed by a dietician who specializes in PKU/metabolic diseases?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Has the patient been compliant with and failed a phenylalanine restricted diet for at least 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Do average Phe levels within 2 weeks of therapy initiation show the following? <ul style="list-style-type: none"> • >6 mg/dL for ages 1 month to 12 years • >15 mg/dL after the age of 12 • >6 mg/dL in pregnancy. 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Is sapropterin dihydrochloride or Palynziq® being requested to liberalize a strict phenylalanine restricted diet? Authorization will not be provided for liberalizing diet or in non-compliant patients.	<input type="checkbox"/>	<input type="checkbox"/>	
7. For Palynziq®, has a trial and failure of the maximally tolerated dose of sapropterin dihydrochloride been demonstrated?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION
Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member remained compliant with a phenylalanine-restricted diet?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has there been a documented positive clinical response from treatment? <ul style="list-style-type: none"> • Defined as a $\geq 20\%$ decrease from baseline in Phe levels after 12 weeks or maintenance of initial reduction. • 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician's Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 059
 Origination Date: 06/04/2018
 Reviewed/Revised Date: 10/28/2020
 Next Review Date: 10/28/2021
 Current Effective Date: 11/01/2020

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.